

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb335</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Enhancing Stability of Destabilized Green Fluorescent Protein Using Chimeric mRNA  Containing Human Beta-Globin 5′ and 3′ Untranslated Regions</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Adibzadeh</surname><given-names>Setare</given-names></name></contrib><aff>Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fardaei</surname><given-names>Majid</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Takhshid</surname><given-names>Mohammad Ali</given-names></name></contrib><aff>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Miri</surname><given-names>Mohammad Reza</given-names></name></contrib><aff>Department of Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rafiei Dehbidi</surname><given-names>Gholam Reza</given-names></name></contrib><aff>Department of Immunology, Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Farhadi</surname><given-names>Ali</given-names></name></contrib><aff>Tehran University of Medical Sciences, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ranjbaran</surname><given-names>Reza</given-names></name></contrib><aff>Department of Anatomy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Alavi</surname><given-names>Parnian</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Nikouyan</surname><given-names>Negin</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Seyyedi</surname><given-names>Noorossadat</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Naderi</surname><given-names>Samaneh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Eskandari</surname><given-names>Alireaz</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Behzad-Behbahani</surname><given-names>Abbas</given-names></name></contrib><aff>Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>11</volume>
      <issue>1</issue>
      <fpage>112</fpage>
      <lpage>117</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>5</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>9</month>
          <year>2017</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;Background: In spite of recent progress in mRNA technologies and their potential applications for treatment of human diseases, problems such as the transient nature of mRNA limit the stability of gene up-regulation and, thus, potentially reduce mRNA efficiency for gene therapy. Using human &amp;beta;-globin 5&amp;prime; and 3&amp;prime; untranslated regions (UTRs), this study aimed to develop the different chimeric constructs of mRNAs to increase the stability of destabilized green fluorescent protein (EGFPd2) in HEK 293 cells.&amp;nbsp;&lt;br /&gt;
Methods: Purified human &amp;beta;-globin (HBG) 5&amp;prime;-3&amp;prime;UTRs, and the coding sequence of destabilized green fluorescent protein (EGFPd2) were amplified separately and ligated to each other using SOEing PCR method in a different format. As controls, the original construct of EGFPd2 under the control of T7 promoter was used. Following &lt;em&gt;in vitro &lt;/em&gt;transcription, HEK 293 cells were then transfected with several constructs and incubated at 37&lt;sup&gt;o&lt;/sup&gt;&lt;em&gt;C&lt;/em&gt; in a CO&lt;sub&gt;2&lt;/sub&gt; incubator. They were monitored under a fluorescence microscope every four hours for the first 24 &lt;em&gt;hr&lt;/em&gt;, then every 12&lt;em&gt; hr&lt;/em&gt; afterwards. The resulting fluorescence was measured as a surrogate for translation efficiency and duration.&amp;nbsp;&lt;br /&gt;
Results: By monitoring the HEK cells over 48 &lt;em&gt;hr&lt;/em&gt;, cells transfected with mRNA with various HBG UTRs showed significantly different fluorescence intensity and stability in comparison with the pEGFPd2 prototype (control transcript) overtime. Overall, the images show that replacement of the 3&amp;prime; UTR end of the prototype vector pGFPd2 with the 3&amp;prime; end of &amp;beta;- globin mRNA increases the half-life of the chimeric mRNA for more than 32 &lt;em&gt;hr&lt;/em&gt;.&amp;nbsp;&lt;br /&gt;
Conclusion: This result indicates that &amp;beta;-globin 3&amp;prime; UTR would definitely increase the half-life of mRNA and may help to decrease the mRNA therapeutic dosage in the treatment of diseases associated with mRNA therapy.&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
